94 related articles for article (PubMed ID: 33225315)
1. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by
Piper-Vallillo AJ; Halbert BT; Rangachari D; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2020 Nov; 1(4):100071. PubMed ID: 33225315
[No Abstract] [Full Text] [Related]
2. Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.
Lim SM; Yang SD; Lim S; Shim HS; Cho BC
JTO Clin Res Rep; 2021 Jun; 2(6):100180. PubMed ID: 34590028
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in
Frigault MM; Markovets A; Nuttall B; Kim KM; Park SH; Gangolli EA; Mortimer PGS; Hollingsworth SJ; Hong JY; Kim K; Kim ST; Barrett JC; Lee J
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923890
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
6. Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.
Kim ST; Lee S; Park M; Park SH; Park JO; Lim HY; Park YS; Kang WK; Gangolli EA; Shin H; Kim KM; Hollingsworth SJ; Mortimer PGS; Lee J
Transl Oncol; 2019 Apr; 12(4):597-601. PubMed ID: 30695737
[TBL] [Abstract][Full Text] [Related]
7.
Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
[TBL] [Abstract][Full Text] [Related]
8. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
10. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
11. Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer.
Zhang Z; Yang S; Wang Q
Biomark Res; 2019; 7():27. PubMed ID: 31832192
[TBL] [Abstract][Full Text] [Related]
12.
Klempner SJ; Mehta P; Schrock AB; Ali SM; Ou SI
Lung Cancer (Auckl); 2017; 8():241-247. PubMed ID: 29255376
[TBL] [Abstract][Full Text] [Related]
13. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with
Zhu VW; Schrock AB; Ali SM; Ou SI
Lung Cancer (Auckl); 2019; 10():21-26. PubMed ID: 30881166
[TBL] [Abstract][Full Text] [Related]
14. Combo Therapy Beats Back Relapsed NSCLC.
Cancer Discov; 2019 Jun; 9(6):685. PubMed ID: 30930332
[TBL] [Abstract][Full Text] [Related]
15. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice.
Higo H; Ohashi K; Makimoto G; Nishii K; Kudo K; Kayatani H; Watanabe H; Kano H; Ninomiya K; Hotta K; Maeda Y; Kiura K
Lung Cancer; 2019 Oct; 136():86-93. PubMed ID: 31470227
[TBL] [Abstract][Full Text] [Related]
18. Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for
Piper-Vallillo AJ; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2021 Mar; 2(3):100133. PubMed ID: 34589996
[No Abstract] [Full Text] [Related]
19. Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring
Simionato F; Calvetti L; Cosci M; Scarparo S; Aprile G
Onco Targets Ther; 2020; 13():12027-12031. PubMed ID: 33262603
[TBL] [Abstract][Full Text] [Related]
20. Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
Yu R; Bai H; Gao B; Li T; He X; Zhang P; Wang J
Thorac Cancer; 2021 Jan; 12(1):128-132. PubMed ID: 33225619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
